Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · Real-Time Price · USD
52.91
+0.91 (1.75%)
At close: Dec 20, 2024, 4:00 PM
52.66
-0.25 (-0.47%)
After-hours: Dec 20, 2024, 6:26 PM EST
Tarsus Pharmaceuticals Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Current | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
Dec '24 Dec 20, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Market Capitalization | 2,023 | 670 | 391 | 465 | 840 | - | |
Market Cap Growth | 115.87% | 71.44% | -15.95% | -44.60% | - | - | |
Enterprise Value | 1,779 | 455 | 185 | 283 | 857 | - | |
Last Close Price | 52.91 | 20.25 | 14.66 | 22.50 | 41.33 | - | |
PS Ratio | 14.82 | 38.42 | 15.15 | 8.16 | - | - | |
PB Ratio | 8.51 | 3.40 | 2.03 | 2.79 | 5.06 | - | |
P/TBV Ratio | 5.47 | 3.47 | 2.03 | 2.79 | 5.06 | - | |
P/FCF Ratio | - | - | - | 147.13 | - | - | |
P/OCF Ratio | - | - | - | 124.13 | - | - | |
EV/Sales Ratio | 13.73 | 26.10 | 7.15 | 4.96 | - | - | |
EV/FCF Ratio | - | - | - | 89.41 | - | - | |
Debt / Equity Ratio | 0.31 | 0.16 | 0.10 | 0.01 | 0.01 | 0.00 | |
Debt / FCF Ratio | - | - | - | 0.38 | - | - | |
Asset Turnover | 0.40 | 0.07 | 0.13 | 0.33 | - | - | |
Quick Ratio | 5.27 | 6.64 | 14.30 | 14.98 | 31.21 | 70.80 | |
Current Ratio | 5.42 | 6.93 | 14.61 | 15.33 | 31.68 | 70.85 | |
Return on Equity (ROE) | -59.56% | -69.71% | -34.53% | -8.31% | -24.01% | -15.67% | |
Return on Assets (ROA) | -27.26% | -36.27% | -19.27% | -4.33% | -14.65% | -8.85% | |
Return on Capital (ROIC) | -31.58% | -40.51% | -20.58% | -4.54% | -15.04% | -8.99% | |
Earnings Yield | -6.64% | -20.27% | -15.88% | -2.97% | -3.19% | - | |
FCF Yield | -5.03% | -17.75% | -12.67% | 0.68% | -2.57% | - | |
Buyback Yield / Dilution | -30.92% | -19.35% | -19.78% | -231.12% | -162.72% | -34.29% | |
Total Shareholder Return | -30.92% | -19.35% | -19.78% | -231.12% | -162.72% | -34.29% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.